Practical management of well differentiated thyroid carcinoma in Korea

Endocrine Journal

Volumn 55, Issue 6, 2008, Pages 1015-1024

  Yong, Sang Lee ^a   Nam, Kee Hyun ^a   Woong, Youn Chung ^a   Hang, Seok Chang ^a   Shigematsu, Naoyuki ^b   Takami, Hiroshi ^c   Kubo, Atsushi ^b   Cheong, Soo Park ^a  

^a Yonsei University College of Medicine   (South Korea)

^b KEIO UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

Author keywords

Practical management; Questionnaire; Well differentiated thyroid carcinoma

Indexed keywords

RADIOACTIVE IODINE; THYROTROPIN;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CERVICAL LYMPH NODE; CLINICAL PRACTICE; COMPARATIVE STUDY; E-MAIL; HEALTH SURVEY; HIGH RISK BEHAVIOR; HORMONAL THERAPY; KOREA; LYMPH NODE DISSECTION; MEDICAL SOCIETY; PAPILLARY CARCINOMA; PATIENT CARE; POSTAL MAIL; QUESTIONNAIRE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; HUMANS; KOREA; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUESTIONNAIRES; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR BURDEN;

EID: 58549083759     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-188     Document Type: Article

References (18)

1. Shigematsu N, Takami H, Ito N, Kubo A (2005) Nationwide survey on the treatment policy for well-differentiated thyroid cancer - Results of a questionnaire distributed at the 37th meeting on the Japanese Society of Thyroid Surgery. Endocr J 52: 479-491.
2. Shigematsu N, Takami H, Kubo A (2006) Unique treatment policy for well-differentiated thyroid cancer in Japan: results of a questionnaire distributed to members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons. Endocr J 53: 829-839.
3. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzaka F, Kuma K, Miyauchi A (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28: 1115-1121.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; The Americal Thyroid Association Guidelines Taskforce (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109-142.
5. Hagag P, Strauss S, Weiss M (1998) Role of ultrasound-guided fine needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 8: 989-995.
6. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C (2005) Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 15: 708-717.
7. National Comprehensive Cancer Network: Thyroid carcinoma, Clinical practice guidelines in oncologyv. 1.2994. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp, 2004.
8. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR (1998) Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129: 622-627.
9. Robbins RJ, Schlumberger M (2005) The evolving role of I-131 for the treatment of differentiated thyroid cancer. J Nucl Med 46: 28S-37S.
10. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagil JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899.
11. Maxon HR 3rd, Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19: 685-718.
12. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
13. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34: 554-564.
14. Vickery AL Jr, Wang CA, Walker AM (1987) Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer 60: 2587-2595.
15. Haugen B, Pacini F, Reiners C, Schlumnerger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877-3885.
16. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini G, Piazza F, Caciagli M, Mariani G (2003) Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88: 4110-4115.
17. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A (1985) Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 23: 405-411.
18. Lim CY, Yun JS, Lee J, Nam KH, Chung WY, Park CS (2007) Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 17: 347-350.